Results 61 to 70 of about 9,342 (275)

Diagnostic conundrums in antenatal presentation of a skeletal dysplasia with description of a heterozygous C-propeptide mutation in COL1A1 associated with a severe presentation of osteogenesis imperfecta [PDF]

open access: yes, 2016
Prompt and accurate diagnosis of skeletal dysplasias can play a crucial role in ensuring appropriate counseling and management (both antenatal and postnatal).
Bonafe   +10 more
core   +1 more source

Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review

open access: yesInternational Journal of Endocrinology, 2023
Objective To summarize the characteristics of all reported patients with hypophosphatasia (HPP) who sustained atypical femoral fracture (AFF) and identify all available evidence to quantify the rate of coexistence between HPP and AFF. Methods Potentially
N. Charoenngam   +6 more
semanticscholar   +1 more source

Excellent response to asfotase alfa treatment in an adolescent patient with hypophosphatasia

open access: yesJIMD Reports, 2021
Hypophosphatasia (HPP) is a rare inherited metabolic disorder characterized by deficient activity of alkaline phosphatase, causing defective mineralization of bones and teeth.
Olivia Sarah Strandbech   +2 more
doaj   +1 more source

Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa

open access: yesCurrent Osteoporosis Reports
Hypophosphatasia (HPP) is a rare, dento-osseous disorder caused by impaired activity of tissue non-specific alkaline phosphatase (TNSALP), a key enzyme in tissue mineralization. This review provides a clinical perspective on the current medical treatment
K. Dahir, Nancy S Dunbar
semanticscholar   +1 more source

Reducing diagnostic delay in hypophosphatasia: a case series of 14 patients presenting to general rheumatology

open access: yesOsteoporosis International, 2023
Objectives Hypophosphatasia (HPP) is a rare genetic metabolic bone disease that can cause chronic pain and fractures. Its hallmark is a persistently low serum ALP.
M. Rauf, J. Kotecha, K. Moss
semanticscholar   +1 more source

Perspective on Dentoalveolar Manifestations Resulting From PHOSPHO1 Loss-of-Function: A Form of Pseudohypophosphatasia?

open access: yesFrontiers in Dental Medicine, 2022
Mineralization of the skeleton occurs by several physicochemical and biochemical processes and mechanisms that facilitate the deposition of hydroxyapatite (HA) in specific areas of the extracellular matrix (ECM). Two key phosphatases, phosphatase, orphan
Fatma F. Mohamed   +6 more
doaj   +1 more source

Az alacsony alkalikusfoszfatáz-aktivitás klinikai értékelése és differenciáldiagnosztikája [PDF]

open access: yes, 2017
Laboratory diagnostics is especially important in the diagnosis of certain diseases. We compared manual measurements results to laboratory normal values. In some cases, these values depend on the gender and age as well.
Fodor, Anna   +2 more
core   +2 more sources

Perinatal Hypophosphatasia in a Premature Infant

open access: yesAmerican Journal of Perinatology Reports, 2020
A premature male infant was delivered at 32 weeks' gestation due to category-2 fetal tracing after preterm labor. The physical exam showed shortened and bowed long bones, with calvarium felt in small area of the head.
Deepika Sankaran   +2 more
doaj   +1 more source

Case Report of Lethal Perinatal Hypophosphatasia with Seizure and Respiratory Failure Diagnosed by ALPL Gene Mutation [PDF]

open access: yesNeonatal Medicine, 2020
Hypophosphatasia is a rare disease characterized by defective bone mineralization due to deficiency of tissue-nonspecific alkaline phosphatase. The patient was an 8-day-old male infant who presented with seizure since that day.
Seung Jae Lee   +2 more
doaj   +1 more source

Mobility and Quality of Life in Adults with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement

open access: yesAdvances in Therapy
Hypophosphatasia (HPP) is a rare disease caused by deficient tissue–non-specific alkaline phosphatase (ALP) activity. Asfotase alfa is a tissue–non-specific ALP enzyme-replacement therapy which was reimbursed in the UK under a Managed Access Agreement ...
Katie E Moss   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy